# Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus

> **NCT03336398** · PHASE2 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 42 (actual)

## Conditions studied

- Tinnitus

## Interventions

- **DRUG:** Ketamine Hydrochloride in saline

## Key facts

- **NCT ID:** NCT03336398
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2023-06-17
- **Final completion:** 2024-07-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336398, "Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03336398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*